HER2-Negative Breast Cancer Recruiting Phase 3 Trials for Fulvestrant (DB00947)

IndicationStatusPhase
DBCOND0072181 (HER2-Negative Breast Cancer)Recruiting3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01953588Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing SurgeryTreatment